• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza v

tetano

Editor, Senior Moderator
Vaccine. 2018 Apr 26. pii: S0264-410X(18)30551-6. doi: 10.1016/j.vaccine.2018.04.054. [Epub ahead of print]
[h=1]A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine.[/h] Hjertner B[SUP]1[/SUP], Bengtsson T[SUP]2[/SUP], Morein B[SUP]3[/SUP], Paulie S[SUP]4[/SUP], Fossum C[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] A preferred adjuvant should promote both Th1 and Th2 responses. However, most adjuvants in common use are biased towards a Th2-driven response. Therefore, the ability of a novel saponin-based adjuvant G3 to inducing balanced Th1 and Th2 responses in BALB/c mice immunized with a split trivalent seasonal influenza vaccine was evaluated in comparison to that of the adjuvant Al(OH)[SUB]3[/SUB]. Clear differences in the IgG profiles induced by G3, Al(OH)[SUB]3[/SUB] or non-adjuvanted vaccine were recorded. Both adjuvants enhanced high and similar levels of the Th2 associated IgG1 subtype compared to mice given vaccine alone. Only G3 enhanced the IgG2a subclass reflecting a Th1 response, whereas Al(OH)[SUB]3[/SUB] even abrogated the IgG2a production. Accordingly, G3 enhanced the production of IL-2 and IFN-γ and also of IL-2/IFN-γ double secreting cells, emphasizing the strong Th1 driving effect of G3. Only Al(OH)[SUB]3[/SUB] increased splenocyte production of IL-17. Taken together, the results indicate a strong propensity for G3 to induce both Th1 and Th2 driven immune responses.


[h=4]KEYWORDS:[/h] Adjuvant; Cytokine production; Influenza; Th1/Th2

PMID: 29706292 DOI: 10.1016/j.vaccine.2018.04.054
 
Back
Top Bottom